1Amani A, Laetitia F, Olivier R, et al, Gemcitabine plus oxaliplatin (GEMOX) combined with cetuxirnab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter carcinoma. Cancer, 112 : 2733-2739.
2Keating (;M, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs, 2009, 69:223-240.
3Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 2006, 66: 11851-11858.
4Roberts PJ, Der CJ. Targeting the Raf-MEK ERK mitogenactivated prolcin k{nase cascade for the treatment of cancer. Oncogene, 2007, 26: 3291-3310.
5Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol, 2004, 57:867-871.
6Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg, 2004, 91: 1354-1360.
7Zhu AX, Duda DG, Sahani DV, et al, Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J, 2009, 15:263-268.
8Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet, 2003, 362:1907-1917.
4[1]Burroughs A,Hochhauser D,Meyer T.Systemic treatment and liver transplantation for hepatocellular carcinoma:two ends of the therapeutic spectrum.Lancet Oncol 2004; 5:409-418
6[3]Torimura T,Sata M,Ueno T,Kin M,Tsuji R,Suzaku K,Hashimoto O,Sugawara H,Tanikawa K.Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.Hum Pathol 1998; 29:986-991
7[4]Yamaguchi R,Yano H,Iemura A,Ogasawara S,Haramaki M,Kojiro M.Expression of vascular endothelial growth factor in human hepatocellular carcinoma.Hepatology 1998; 28:68-77
8[5]Kenyon BM,Browne F,D'Amato RJ.Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.Exp Eye Res 1997; 64:971-978
9[6]Peuckmann V,Fisch M,Bruera E.Potential novel uses of thalidomide:focus on palliative care.Drugs 2000; 60:273-292
